Systematic review of the efficacy, effectiveness and safety of cell-based seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
Optaflu
cell-based
influenza
systematic review
vaccine effectiveness
Journal
Reviews in medical virology
ISSN: 1099-1654
Titre abrégé: Rev Med Virol
Pays: England
ID NLM: 9112448
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
19
01
2022
received:
16
11
2021
accepted:
20
01
2022
medline:
8
5
2023
pubmed:
10
2
2022
entrez:
9
2
2022
Statut:
ppublish
Résumé
The most effective means of preventing seasonal influenza is through strain-specific vaccination. In this study, we investigated the efficacy, effectiveness and safety of cell-based trivalent and quadrivalent influenza vaccines. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs) were eligible for inclusion. Two reviewers independently screened, extracted data and assessed the risk of bias of included studies. Certainty of evidence for key outcomes was assessed using the GRADE methodology. The search returned 28,846 records, of which 868 full-text articles were assessed for relevance. Of these, 19 studies met the inclusion criteria. No relative efficacy data were identified for the direct comparison of cell-based vaccines compared with traditional vaccines (egg-based). Efficacy data were available comparing cell-based trivalent influenza vaccines with placebo in adults (aged 18-49 years). Overall vaccine efficacy was 70% against any influenza subtype (95% CI 61%-77%, two RCTS), 82% against influenza A(H1N1) (95% CI 71%-89%, 2 RCTs), 72% against influenza A(H3N2) (95% CI 39%-87%, 2 RCTs) and 52% against influenza B (95% CI 30%-68%, 2 RCTs). Limited and heterogeneous data were presented for effectiveness when compared with no vaccination. One NRSI compared cell-based trivalent and quadrivalent vaccination with traditional trivalent and quadrivalent vaccination, finding a small but significant difference in favour of cell-based vaccines for influenza-related hospitalisation, hospital encounters and physician office visits. The safety profile of cell-based trivalent vaccines was comparable to traditional trivalent influenza vaccines. Compared with placebo, cell-based trivalent influenza vaccines have demonstrated greater efficacy in adults aged 18-49 years. Overall cell-based vaccines are well-tolerated in adults, however, evidence regarding the effectiveness of these vaccines compared with traditional seasonal influenza vaccines is limited.
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2332Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Ferro A, Bordin P, Benacchio L, et al. Influenza vaccination and absenteeism among healthy working adults: a cost-benefit analysis. Annali di igiene: medicina preventiva e di comunita. 2020;32(3):234-244.
Putri W, Muscatello DJ, Stockwell MS, Newall AT. Economic burden of seasonal influenza in the United States. Vaccine. 2018;36(27):3960-3966.
Rajaram S, Boikos C, Gelone DK, Gandhi A. Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Ther Adv Vaccines Immunother. 2020;8:2515135520908121.
Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36-44.
Skowronski DM, Chambers C, Sabaiduc S, et al. Interim estimates of 2014/2015 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Eur Commun Dis Bull (Euro Surveill: Bulletin Europeen sur les maladies transmissibles). 2015;20(4).
Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-2013 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PloS one. 2014;9(3):e92153.
Wu NC, Zost SJ, Thompson AJ, et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 2017;13(10):e1006682-e.
Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. New technologies for influenza vaccines. Microorganisms. 2020;8(11):1745.
Milián E, Kamen AA. Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int. 2015;2015:504831.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane; 2021. version 6.2 (updated February 2021). http://www.training.cochrane.org/handbook.version 6.2
Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14(1):25.
Thorlund K, Wetterslev J, Awad T, Thabane L, Gluud C. Comparison of statistical inferences from the DerSimonian-Laird and alternative random-effects model meta-analyses-an empirical assessment of 920 Cochrane primary outcome meta-analyses. Res synthesis methods. 2011;2(4):238-253.
Bender R, Friede T, Koch A, et al. Methods for evidence synthesis in the case of very few studies. Res synthesis methods. 2018;9(3):382-392.
Jackson D, Turner R. Power analysis for random-effects meta-analysis. Res synthesis methods. 2017;8(3):290-302.
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394.
Schünemann HJ, Cuello C, Akl EA, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105-114.
Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England). 2011;377(9767):751-759.
Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010;51(9):997-1004.
Bruxvoort KJ, Luo Y, Ackerson B, et al. Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017-2018. Vaccine. 2019;37(39):5807-5811.
Castilla J, Navascués A, Fernández-Alonso M, et al. Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons. Vaccine. 2016;34(11):1350-1357.
DeMarcus L, Shoubaki L, Federinko S. Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017-2018 influenza season. Vaccine. 2019;37(30):4015-4021.
Izurieta HS, Chillarige Y, Kelman J, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017-2018. J Infect Dis. 2019;220(8):1255-1264.
Bart S, Cannon K, Herrington D, et al. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: a Phase III, double-blind, multicenter, randomized, non-inferiority study. Hum Vaccin Immunother. 2016;12(9):2278-2288.
Choi WS, Noh JY, Song JY, et al. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): a randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects. Hum Vaccin Immunother. 2017;13(7):1653-1660.
Ehrlich HJ, Berezuk G, Fritsch S, et al. Clinical development of a Vero cell culture-derived seasonal influenza vaccine. Vaccine. 2012;30(29):4377-4386.
Ehrlich HJ, Singer J, Berezuk G, et al. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis. 2012;54(7):946-954.
Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine. 2009;27(5):786-791.
Hall GC, Davies PTG, Karim MY, Haag MDM, O'Leary C. Observational safety study of specific outcomes after trivalent cell culture seasonal influenza vaccination (Optaflu(®) among adults in THIN database of electronic UK primary healthcare records. Pharmacoepidemiol drug Saf. 2018;27(1):52-58.
Halperin SA, Smith B, Mabrouk T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine. 2002;20(7-8):1240-1247.
Loebermann M, Fritzsche C, Geerdes-Fenge H, Heijnen E, Kirby D, Reisinger EC. A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults. Infection. 2019;47(1):105-109.
Loebermann M, Voss U, Meyer S, et al. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination. PloS one. 2013;8(8):e70866.
Song JY, Cheong HJ, Lee J, et al. Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): a randomized, double-blind, multi-center, phase 3 clinical trial. Vaccine. 2015;33(41):5437-5444.
Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis. 2009;200(6):841-848.
Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, et al. Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons. Hum Vaccin Immunother. 2012;8(5):645-652.
Vinnemeier CD, Fischer-Herr J, Meyer S, et al. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study. Hum Vaccin Immunother. 2014;10(2):441-448.
Tricco AC, Chit A, Soobiah C, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC medicine. 2013;11:153.
Rajaram S, Suphaphiphat P, van Boxmeer J, et al. Retrospective assessment of the antigenic similarity of egg-propagated and cell culture-propagated reference influenza viruses as compared with circulating viruses across influenza seasons 2002-2003 to 2017-2018. Int J Environ Res public health. 2020;17(15).
Peck H, Laurie KL, Rockman S, et al. Enhanced isolation of influenza viruses in qualified cells improves the probability of well-matched vaccines. NPJ vaccines. 2021;6(1):149.
Pérez Rubio A, Eiros JM. Cell culture-derived flu vaccine: present and future. Hum Vaccin Immunother. 2018;14(8):1874-1882.
Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane database Syst Rev. 2018;2(2):Cd001269.
DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31(1):49-57.
Chen J-R, Liu Y-M, Tseng Y-C, Ma C. Better influenza vaccines: an industry perspective. J Biomed Sci. 2020;27(1):33.
Paules CI, Sullivan SG, Subbarao K, Fauci AS. Chasing seasonal influenza - the need for a universal influenza vaccine. N. Engl J Med. 2018;378(1):7-9.
Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci. 2017;114(47):12578-12583.
Flannery B, Chung JR, Belongia EA, et al. Interim estimates of 2017-2018 seasonal influenza vaccine effectiveness-United States, February 2018. MMWR Morb Mortal Wkly Rep. 2018;67(6):180-185.
European Centre for Disease Prevention and Control. Seasonal influenza vaccination and antiviral use in EU/EEA Member States-Overview of vaccine recommendations for 2017-2018 and vaccination coverage rates for 2015-2016 and 2016-2017 influenza seasons. Stockholm. ECDC. 2018. https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-antiviral-use-eu-eea-member-states
Lipsitch M. Challenges of vaccine effectiveness and waning studies. Clin Infect Dis. 2018;68(10):1631-1633.
Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane database Syst Rev. 2017;2:Mr000033.
Boikos C, Fischer L, O'Brien D, Vasey J, Sylvester GC, Mansi JA. Relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018-2019 influenza season in the United States. Clin Infect Dis. 2021;73(3):e692-e698.
Boikos C, Sylvester GC, Sampalis JS, Mansi JA. Relative effectiveness of the cell-cultured quadrivalent influenza vaccine compared to standard, egg-derived quadrivalent influenza vaccines in preventing influenza-like illness in 2017-2018. Clin Infect Dis. 2020;71(10):e665-e671.
Divino V, Krishnarajah G, Pelton SI, et al. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-2018 influenza season. Vaccine. 2020;38(40):6334-6343.
Izurieta HS, Lu M, Kelman J, et al. Comparative effectiveness of influenza vaccines among US medicare beneficiaries ages 65 Years and older during the 2019-2020 season. Clin Infect Dis. 2021;73(11):e4251-e4259.
Klein NP, Fireman B, Goddard K, et al. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-2018 influenza season. PloS one. 2020;15(2):e0229279-e.
Martin ET, Cheng C, Petrie JG, et al. Low influenza vaccine effectiveness against A(H3N2)-associated hospitalizations in 2016-2017 and 2017-2018 of the hospitalized adult influenza vaccine effectiveness Network (HAIVEN). J Infect Dis. 2021;223(12):2062-2071.
Krishnarajah G, Divino V, Postma MJ, et al. Clinical and economic outcomes associated with cell-based quadrivalent influenza vaccine vs. Standard-dose egg-based quadrivalent influenza vaccines during the 2018-2019 influenza season in the United States. Vaccines. 2021;9(2).